$41.34 $0.40 (1.0%)

03:28 PM EDT on 05/29/20

Esperion Therapeutics (NASDAQ:ESPR)

CAPS Rating: 4 out of 5

Current Price $41.34 Mkt Cap $1.1B
Open $40.93 P/E Ratio 0.00
Prev. Close $40.94 Div. (Yield) $0.00 (0.0%)
Daily Range $39.65 - $41.62 Volume 397,750
52-Wk Range $24.82 - $76.98 Avg. Daily Vol. 704,448

Caps

How do you think NASDAQ:ESPR will perform against the market?

Add Stock to CAPS Watchlist

All Players

64 Outperform
10 Underperform
 

All-Star Players

15 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ESPR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

solmyr45 (73.12)
Submitted January 03, 2020

ESPR is all in on bempedoic acid, which reduces LDL-C cholesterol in statin-resistant/intolerant patients (meaning folks who have intolerable side effects from Lipitor). Massive potential given market size. IPO 2013 at $17. Broke $105 in '15, sunk to… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:ESPR VS S&P 500 (SPY)

Fools bullish on NASDAQ:ESPR are also bullish on:

Fools bearish on NASDAQ:ESPR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ESPR.

Recs

0
Member Avatar screach (90.76) Submitted: 4/4/2020 1:21:14 PM : Outperform Start Price: $32.05 NASDAQ:ESPR Score: +9.17

blockbuster drug approval not reflected in stock price. What's not to like?

Recs

0
Member Avatar tamvanta66 (77.26) Submitted: 2/21/2020 11:00:25 PM : Outperform Start Price: $62.53 NASDAQ:ESPR Score: -28.94

Good Pipeline

Recs

7
Member Avatar solmyr45 (73.12) Submitted: 1/3/2020 12:01:03 AM : Outperform Start Price: $60.58 NASDAQ:ESPR Score: -27.09

ESPR is all in on bempedoic acid, which reduces LDL-C cholesterol in statin-resistant/intolerant patients (meaning folks who have intolerable side effects from Lipitor). Massive potential given market size. IPO 2013 at $17. Broke $105 in '15, sunk to $10 in '16, and now back up to $60. Lots of cash piled up.

Their leadership has skin in the game. The CEO has a huge salary ($9m vs. $3m industry avg) and is involved with several other companies, but has purchased $1.5m worth of ESPR in the last 10 months over seven purchases. Most recent purchase was $37 Nov. '19. Before this year, he hadn't bought any since '16. No insider sells since March '19.

Risk: Stock is overbought (87 RSI14) but shows strong technical signals. Found multiple analyses calling it a buy or strong buy. Price targets range from $65 to $144.

This is a one-drug company, adding to the investment risk. It's all or nothing. But this drug fills a gap for the ~18m Americans who don't have any other ways to lower their cholesterol.

Better news: A company (Daiichi Sankyo) paid $150m up front in Jan. 2019 to win rights to sell this drug in Europe, with another $150m due to ESPR upon the first sale. Combined with the CEO's personal investments, we're seeing a lot of insider faith here.

Up next are another round of major bureaucratic (PDUFA) approvals in Feb. 2020. If approved, the stock could spike afterward. FDA showed rare trust by approving both variants of the drug in 2019 without convening an advisory panel, indicating possible fast-tracking to market. Investors expect $100+ share price if approved.

Leaderboard

Find the members with the highest scoring picks in ESPR.

Score Leader

TerryHoodSr

TerryHoodSr (60.48) Score: +648.65

The Score Leader is the player with the highest score across all their picks in ESPR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
superstar2 99.30 7/6/2016 Outperform 5Y $10.33 +294.29% +45.09% +249.20 0 Comment
gunda7907 < 20 12/11/2013 Outperform 5Y $12.51 +225.58% +69.36% +156.22 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 71.14 2/3/2017 Outperform 5Y $14.98 +171.90% +32.60% +139.30 0 Comment
dollarsandcents1 < 20 1/19/2016 Outperform 5Y $14.31 +184.63% +60.04% +124.58 0 Comment
mgelinas < 20 4/28/2014 Outperform 5Y $14.21 +186.63% +62.53% +124.10 0 Comment
cclark04 62.72 3/23/2015 Underperform 3M $109.73 -62.88% +44.31% +107.19 0 Comment
AntMan56 51.18 3/23/2015 Underperform 5Y $109.73 -62.88% +44.31% +107.19 0 Comment
Avi12 59.31 3/23/2015 7/8/2017 Underperform 3Y $109.73 -62.88% +44.31% +107.19 0 Comment
GuruGrowth 59.51 3/25/2015 Underperform 5Y $102.74 -60.36% +45.42% +105.77 0 Comment
portefeuille2 99.29 9/17/2014 10/31/2019 Outperform 5Y $15.85 +156.97% +51.43% +105.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ESPR.